Speaking Out on Non-Small Cell Lung Cancer


In this episode of the “CURE Talks Cancer” podcast, we spoke with Andrew Ciupek, from the Go2 Foundation for Lung Cancer, on the importance of biomarker testing and targeted therapy options for patients with non-small cell lung cancer.

While the treatment landscape for non-small cell lung cancer (NSCLC) continues to evolve, there is a heavy emphasis on discovering new targeted therapies for patients.

Because of this, it is key for patients to have their tumors tested for biomarkers to determine if they have a mutation, like EGFR, ROS1, ALK, BRAF, that could determine what treatment they should undergo. For example, Tagrisso (osimertinib) is approved by the Food and Drug Administration to treat patients with NSCLC with an EGFR mutation.

In this episode, we spoke with Andrew Ciupek, manager of clinical research at the Go2 Foundation for Lung Cancer, to learn more about biomarker testing and the various treatment options available for patients with NSCLC.

Related Content